Adipotide is an experimental prohibitin‑targeting peptide that has been studied in animals for rapid fat loss, and the community typically administers it at 1 mg per day (doses ranging from 1 to 5 mg) with no standardized timing or cycling reported. Because it has no FDA‑approved indication, any human use is off‑label or compounded, and injection‑site reactions and other common side effects have not emerged as consistent reports. Searches have not identified consistent reports of injection‑site reactions, histamine flush, sleep disturbances, edema, nausea, or other issues.
Data last updated
Measured on 3 of 6 axes
Evidence shape
Adipotide currently lacks any clinical evidence, as there are no published human studies or registered trials for this peptide. Because no human data exists to support its use for any indication, the research profile remains entirely empty. This absence of clinical documentation means there is no basis for evaluating its efficacy or safety in human subjects, and the peptide has not progressed through the standard research pipeline required to establish a therapeutic profile.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How ADIPOTIDE is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Most community users take 1 mg once daily, while a smaller group reports up to 5 mg per day; no cycling pattern was noted.